In Re Swine Flu Immunization Products Liability Litigation

446 F. Supp. 244
CourtUnited States Judicial Panel on Multidistrict Litigation
DecidedMarch 21, 1978
Docket330
StatusPublished
Cited by15 cases

This text of 446 F. Supp. 244 (In Re Swine Flu Immunization Products Liability Litigation) is published on Counsel Stack Legal Research, covering United States Judicial Panel on Multidistrict Litigation primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
In Re Swine Flu Immunization Products Liability Litigation, 446 F. Supp. 244 (jpml 1978).

Opinion

OPINION AND ORDER

PER CURIAM.

I. Background of the Litigation

This litigation presently consists of 26 actions pending in seventeen federal districts. The distribution of the actions is as follows:

Northern District of Alabama 5
Northern District of California 2
Eastern District of California 2
Southern District of New York 2
District of Minnesota 2
District of Hawaii 2
Northern District of New York 1
Northern District of Oklahoma 1
Northern District of Ohio 1
Southern District of Florida 1
Western District of Michigan 1
Eastern District of Missouri 1
Eastern District of Pennsylvania 1
Middle District of Tennessee 1
District of Colorado 1
District of Arizona 1
District of Vermont 1

These actions involve claims for personal injuries or wrongful death resulting from administration of swine flu vaccinations under the National Swine Flu Immunization Program of 1976, 42 U.S.C. § 247b(j)-(7). The legislation provided that the United States would assume exclusive liability, with certain limitations, for all personal injuries or deaths resulting from manufacture, distribution or administration of vaccine under the swine flu program. 42 U.S.C. § 247b(k). The legislation further provided that, with certain modifications, the customary procedures for filing tort claims against the United States must be followed. Id. Those procedures require a claimant to file a written notice of claim with the United States and, if the claim is not resolved within six months, it is deemed to have been disallowed and the claimant is entitled to file suit in federal court on the claim. 28 U.S.C. § 2675. The present actions allegedly have been filed after compliance with those procedures.

The United States is the sole defendant in all except two of the actions. 1 Plaintiffs in the actions generally allege that the swine flu vaccine was improperly devel *246 oped, researched, tested, manufactured, marketed, distributed, promoted and administered. In particular, plaintiffs allege that the risks of injuries and neurological complications that might result from administration of the vaccine were inadequately disclosed. Liability is claimed under theories of, inter alia, negligence, strict liability, fraudulent misrepresentation and breach of express and implied warranties. The injuries most frequently alleged are paralysis, a particular type of paralysis known as Guillain-Barre Syndrome, loss of sensation and death. Plaintiff in the action pending in the Southern District of Florida (Reichlin) seeks to represent a class consisting of all individuals who have contracted GuillainBarre Syndrome as a proximate result of having been inoculated with swine flu vaccine. The other 25 actions are individual actions.

II. Proceedings Before the Panel

Pursuant to 28 U.S.C. § 1407(c)(i) and Rule 8, R.P.J.P.M.L., 65 F.R.D. 253, 258-59 (1975), the Panel ordered the parties to show cause why these 26 actions should not be transferred to a single district for coordi: nated or consolidated pretrial proceedings. 2 The plaintiffs in several actions favor transfer. The United States and plaintiffs in several other actions oppose transfer. A number of different transferee forums have been suggested by the parties.

We find that these actions involve common questions of fact and that their transfer under Section 1407 to the District of the District of Columbia for coordinated or consolidated pretrial proceedings will serve the convenience of the parties and witnesses and promote the just and efficient conduct of this litigation.

III. The Question of Transfer

Although the United States and some of the other parties opposing transfer recognize that these actions involve common questions of fact regarding pertinent scientific and medical data, the parties opposing transfer contend that individual factors predominate in each action. For example, they urge that the types and degrees of injuries vary; that causation varies significantly with individual factors such as age, medical history, and the amount of time that elapsed from receipt of the vaccine until the onset of injuries; that the substantive law applicable in each action will be that of the state wherein each action was filed; and that liability questions against the United States differ because in actuality the United States stands in the shoes of a number of participants in the swine flu program, including the five manufacturers of the swine flu vaccine and the numerous local groups that administered the vaccine. In addition, some opponents maintain that transfer will cause undue expense to plaintiffs of limited financial means and that, because new actions will continuously be filed, pretrial proceedings in the actions in this litigation will be in many different stages and therefore coordination or consolidation of these proceedings will be difficult. 3

We find these arguments unpersuasive. Although we acknowledge that the swine flu actions differ in certain respects, we are persuaded that all these actions involve substantial common questions of fact concerning the development, production, testing and administration of the swine flu vaccine. *247 Scientific knowledge concerning the efficacy of the swine flu vaccine and the potential risks involved in administration of the vaccine is relevant to all actions. Transfer is thus necessary in order to prevent duplicative discovery concerning the same documents and witnesses and to eliminate the possibility of conflicting pretrial rulings. Any discovery unique to a particular action can be scheduled by the transferee judge to proceed concurrently with the common discovery, which will allow the litigation to proceed expeditiously in all areas. See In re Republic National-Realty Equities Securities Litigation, 382 F.Supp. 1403, 1405-06 (Jud.Pan.Mult.Lit.1974).

The concern that transfer might be financially burdensome to plaintiffs of limited financial means is unwarranted.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Walker v. Merck & Co., Inc.
W.D. North Carolina, 2022
Bettie Keown Daniels v. United States
704 F.2d 587 (Eleventh Circuit, 1983)
Baum v. United States
541 F. Supp. 1349 (M.D. Pennsylvania, 1982)
In re Swine Flu Immunization Products Liability Litigation
89 F.R.D. 695 (District of Columbia, 1980)
In Re Data General Corp. Antitrust Litigation
470 F. Supp. 855 (Judicial Panel on Multidistrict Litigation, 1979)
Porter v. United States
464 F. Supp. 949 (Judicial Panel on Multidistrict Litigation, 1979)
In Re Swine Flu Immunization Products Litigation
464 F. Supp. 949 (Judicial Panel on Multidistrict Litigation, 1979)
Heitz v. County of Sacramento
87 Cal. App. 3d 754 (California Court of Appeal, 1978)
In Re Swine Flu Immunization Products Liability Litigation
453 F. Supp. 648 (Judicial Panel on Multidistrict Litigation, 1978)

Cite This Page — Counsel Stack

Bluebook (online)
446 F. Supp. 244, Counsel Stack Legal Research, https://law.counselstack.com/opinion/in-re-swine-flu-immunization-products-liability-litigation-jpml-1978.